Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Equity (2021 - 2024)

Immuneering (IMRX) has 4 years of Return on Equity data on record, last reported at 0.95% in Q3 2024.

  • For Q3 2024, Return on Equity fell 47.0% year-over-year to 0.95%; the TTM value through Sep 2024 reached 0.95%, down 47.0%, while the annual FY2023 figure was 0.55%, 17.0% down from the prior year.
  • Return on Equity reached 0.95% in Q3 2024 per IMRX's latest filing, down from 0.79% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.58% in Q2 2021 and bottomed at 0.95% in Q3 2024.
  • Average Return on Equity over 4 years is 0.35%, with a median of 0.44% recorded in 2022.
  • The widest YoY moves for Return on Equity: up -1bps in 2022, down -90bps in 2022.
  • A 4-year view of Return on Equity shows it stood at 0.21% in 2021, then crashed by -104bps to 0.44% in 2022, then fell by -29bps to 0.56% in 2023, then plummeted by -69bps to 0.95% in 2024.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.95% in Q3 2024, 0.79% in Q2 2024, and 0.66% in Q1 2024.